492 related articles for article (PubMed ID: 16601834)
1. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
2. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
3. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
[TBL] [Abstract][Full Text] [Related]
5. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
6. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity.
Urano T; Ihara H; Suzuki Y; Takada Y; Takada A
Semin Thromb Hemost; 2000; 26(1):39-42. PubMed ID: 10805280
[TBL] [Abstract][Full Text] [Related]
7. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
8. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
10. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors.
Rezaie AR
Biochemistry; 1999 Nov; 38(44):14592-9. PubMed ID: 10545182
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
Charlton PA; Faint RW; Bent F; Bryans J; Chicarelli-Robinson I; Mackie I; Machin S; Bevan P
Thromb Haemost; 1996 May; 75(5):808-15. PubMed ID: 8725728
[TBL] [Abstract][Full Text] [Related]
12. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK; Mestries JC; Gascon MP; Ythier A
Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
Urano T; Wu K; Ihara H; Takada Y; Takada A
Pol J Pharmacol; 1996; 48(2):209-13. PubMed ID: 9112653
[TBL] [Abstract][Full Text] [Related]
14. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
Urano T; Ihara H; Takada Y; Fujie M; Takada A
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
[TBL] [Abstract][Full Text] [Related]
15. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
16. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
Barrowcliffe TW; Thomas DP
Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
Rezaie AR
Biochemistry; 1998 Sep; 37(38):13138-42. PubMed ID: 9748320
[TBL] [Abstract][Full Text] [Related]
19. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin.
Urano T; Ihara H; Takada Y; Nagai N; Takada A
Biochim Biophys Acta; 1996 Dec; 1298(2):199-208. PubMed ID: 8980646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
